342 related articles for article (PubMed ID: 30264678)
1. Targeting PD-L1 Protein: Translation, Modification and Transport.
Wei R; Guo L; Wang Q; Miao J; Kwok HF; Lin Y
Curr Protein Pept Sci; 2019; 20(1):82-91. PubMed ID: 30264678
[TBL] [Abstract][Full Text] [Related]
2. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Fiedler M; Schulz D; Piendl G; Brockhoff G; Eichberger J; Menevse AN; Beckhove P; Hautmann M; Reichert TE; Ettl T; Bauer RJ
Exp Cell Res; 2020 Nov; 396(1):112259. PubMed ID: 32898555
[TBL] [Abstract][Full Text] [Related]
3. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
Front Immunol; 2019; 10():1337. PubMed ID: 31258527
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
Liu M; Sun Q; Wei F; Ren X
Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
[TBL] [Abstract][Full Text] [Related]
5. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
6. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
7. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
8. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Liu D; Wang S; Bindeman W
J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
11. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
Del Re M; van Schaik RHN; Fogli S; Mathijssen RHJ; Cucchiara F; Capuano A; Scavone C; Jenster GW; Danesi R
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188463. PubMed ID: 33137405
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
15. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
Liu H; Bi X; Zhou Y; Shi R; Yao S; Qi J; Feng H; Feng M; Yan J; Tan S
Signal Transduct Target Ther; 2020 Aug; 5(1):158. PubMed ID: 32839442
[No Abstract] [Full Text] [Related]
16. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
Hirsch L; Zitvogel L; Eggermont A; Marabelle A
Br J Cancer; 2019 Jan; 120(1):3-5. PubMed ID: 30413824
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
Skafi N; Fayyad-Kazan M; Badran B
Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
[TBL] [Abstract][Full Text] [Related]
18. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
20. Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Schulz D; Streller M; Piendl G; Brockhoff G; Reichert TE; Menevse AN; Beckhove P; Hautmann MG; Bauer RJ; Ettl T
Carcinogenesis; 2020 Jul; 41(7):984-992. PubMed ID: 31637423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]